The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models

Marc Masanas; Nuria Masiá; Leticia Suárez-Cabrera; Mireia Olivan; Aroa Soriano; Blanca Majem; Laura Devis-Jauregui; Rebeca Burgos-Panadero; Carlos Jiménez; Pau Rodriguez-Sodupe; Ariadna Boloix; Ignasi Toledano; Gabriela Guillén; Alexandra Navarro; David Llobet-Navas; Alberto Villanueva; Josep Sánchez de Toledo; Josep Roma; Rosa Noguera; Lucas Moreno; Rolf Krauss; Soledad Gallego; Anna Santamaria; Miguel F Segura

doi:10.1002/ctm2.533

The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models

Clin Transl Med. 2021 Oct;11(10):e533. doi: 10.1002/ctm2.533.

Authors

Marc Masanas¹, Nuria Masiá², Leticia Suárez-Cabrera², Mireia Olivan^{2

3}, Aroa Soriano¹, Blanca Majem², Laura Devis-Jauregui⁴, Rebeca Burgos-Panadero^{5

6}, Carlos Jiménez¹, Pau Rodriguez-Sodupe⁷, Ariadna Boloix¹, Ignasi Toledano², Gabriela Guillén^{1

8}, Alexandra Navarro⁹, David Llobet-Navas^{4

6}, Alberto Villanueva^{10

11}, Josep Sánchez de Toledo^{1

12}, Josep Roma¹, Rosa Noguera^{5

6}, Lucas Moreno^{1

13}, Rolf Krauss¹⁴, Soledad Gallego^{1

13}, Anna Santamaria², Miguel F Segura¹

Affiliations

¹ Group of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
² Cell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
³ Translational Oncology Laboratory, Anatomy Unit, Department of Pathology and Experimental Therapy, School of Medicine, Universitat de Barcelona (UB), L'Hospitalet de Llobregat, Spain.
⁴ Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.
⁵ Group of Translational Research in Pediatric Solid Tumors Department of Pathology, Medical School, University of Valencia-INCLIVA Biomedical Health Research Institute, Valencia, Spain.
⁶ Low Prevalence Tumors. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
⁷ Quantitative Genomic Medicine Laboratory, qGenomics, Barcelona, Spain.
⁸ Department of Surgery, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
⁹ Department of Pathology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
¹⁰ Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.
¹¹ Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, Barcelona, Spain.
¹² Catalan Institute of Oncology (ICO), Barcelona, Spain.
¹³ Pediatric Oncology and Hematology Department, Hospital Universitari Vall d'Hebron - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
¹⁴ 4SC, Martinsried, Germany.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Animals
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / pharmacology*
Cell Line, Tumor
Disease Models, Animal
Humans
Kinesins / antagonists & inhibitors*
Mice
Neuroblastoma / drug therapy*
Neuroblastoma / pathology
Neuroblastoma / secondary

Substances

Antineoplastic Agents
KIF11 protein, human
Kinesins